BioSpace News Archive

Chemomab Therapeutics Ltd. today announced the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023.

InMode Ltd., a leading global provider of innovative medical technologies, announced that it expects to release its financial results for the first quarter of 2023 before the Nasdaq market opens on Tuesday, May 2, 2023.

Leap Therapeutics, Inc. today announced that enrollment has been completed in Part A of the Phase 2 DeFianCe study evaluating DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Wednesday, April 19, 2023 in Boston, MA.

SciNeuro Pharmaceuticals today announced that SNP318, a novel Lp-PLA2 inhibitor, is advancing into Phase 1 clinical trials in Australia, positioning it for global development.

ESSA Pharma Inc. today announced that the Company has entered into a clinical trial support agreement with Janssen Research & Development, LLC (“Janssen”) to enable evaluation of ESSA’s first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023.

Intera Oncology ® Inc. will showcase its Intera 3000 HAI pump as a sponsor of the 10th annual Cholangiocarcinoma Foundation Conference April 12 to 15 in Salt Lake City, Utah.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, is presenting two posters at the 55th Gatlinburg Conference, being held April 10-13, 2023, in Kansas City, Mo.